• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware) (Amendment)

    2/9/24 4:30:19 PM ET
    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email
    SC 13G/A 1 sc13ga410022atnm_02092024.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 4)1

     

    Actinium Pharmaceuticals, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001 per share

     (Title of Class of Securities)

    00507W206

     (CUSIP Number)

    December 31, 2023

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         441,104 shares of Common Stock
    33,203 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              441,104 shares of Common Stock
    33,203 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            441,104 shares of Common Stock
    33,203 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock, $.001 par value per share (the “Common Stock”) held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    2

    CUSIP No. 00507W206

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         441,104 shares of Common Stock
    33,203 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              441,104 shares of Common Stock
    33,203 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            441,104 shares of Common Stock
    33,203 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Common Stock held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    3

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.0%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Common Stock held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    4

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.0%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Common Stock held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    5

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            District 2 GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.0%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of all of the Issuer’s Common Stock held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    6

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            826,428 shares of Common Stock
    96,666 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.0%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Common Stock held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    7

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            Michael Bigger  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         177,670 shares of Common Stock  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,717,532 shares of Common Stock*
    129,869 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              177,670 shares of Common Stock  
        8   SHARED DISPOSITIVE POWER  
               
              1,717,532 shares of Common Stock*
    129,869 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,895,202 shares of Common Stock*
    129,869 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            6.8%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

    * Consists of 441,104 shares of Common Stock owned by Bigger Capital, 33,203 shares of Common Stock issuable upon exercise of Warrants owned by Bigger Capital, 826,428 shares of Common Stock owned by District 2 CF, 96,666 shares of Common Stock issuable upon exercise of Warrants owned by District 2 CF, 177,670 shares of Common Stock held by Mr. Bigger through an IRA and another account, 150,000 shares of Common Stock through an IRA held by Patricia Winter, the spouse of Mr. Bigger and an aggregate of 300,000 shares of Common Stock through an IRA held by the sons of Mr. Bigger. As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).  

    8

    CUSIP No. 00507W206

     

      1   NAME OF REPORTING PERSON  
             
            Patricia Winter  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Austria  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         150,000 shares*  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         0  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              150,000 shares*  
        8   SHARED DISPOSITIVE POWER  
               
              0  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            150,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

    * Consists of 150,000 shares of Common Stock held through an IRA. Excludes shares deemed beneficially owned by Michael Bigger, the spouse of Ms. Winter.  

    9

    CUSIP No. 00507W206

    Item 1(a).Name of Issuer:

    Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    100 Park Avenue
    23rd Floor
    New York, New York 10017

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

    Bigger Capital Fund, LP (“Bigger Capital”)

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Delaware

     

    Bigger Capital Fund GP, LLC (“Bigger GP”)

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Delaware

     

    District 2 Capital Fund LP (“District 2 CF”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Capital LP (“District 2”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 GP LLC (“District 2 GP”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Holdings LLC (“District 2 Holdings”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    Michael Bigger

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: USA

     

    10

    CUSIP No. 00507W206

    Patricia Winter

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Austria

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Item 2(d).Title of Class of Securities:

    Common Stock, $0.001 par value (the “Common Stock”).

    Item 2(e).CUSIP Number:

    00507W206

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    11

    CUSIP No. 00507W206

    Item 4.Ownership
    (a)Amount beneficially owned:

    As of December 31, 2023, Bigger Capital beneficially owned 441,104 shares of Common Stock, and an aggregate of 33,203 shares of Common Stock currently issuable upon the exercise of Warrants with varying exercise prices per share (collectively the “Warrants”). As described below, the Warrants contain a 4.99% beneficial ownership limitation.

    Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the 441,104 shares of Common Stock and 33,203 shares of Common Stock issuable upon exercise of Warrants beneficially owned by Bigger Capital.

    As of December 31, 2023, District 2 CF beneficially owned 826,428 shares of Common Stock, and 96,666 shares of Common Stock issuable upon the exercise of Warrants owned by District 2 CF. As described below, the Warrants contain a 4.99% beneficial ownership limitation.

    District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 826,428 shares of Common Stock beneficially owned by District 2 CF and the 96,666 shares of Common Stock issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the 826,428 shares of Common Stock beneficially owned by District 2 CF and the 96,666 shares of Common Stock issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 826,428 shares of Common Stock beneficially owned by District 2 CF and the 96,666 shares of Common Stock issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    Mr. Bigger, as the managing member of Bigger GP and the managing member of District 2 Holdings, may be deemed to beneficially own the (i) 441,104 shares of Common Stock beneficially owned by Bigger Capital, (ii) 826,428 shares of Common Stock beneficially owned by District 2 CF, (iii) 33,203 shares of Common Stock issuable upon exercise of Warrants owned by Bigger Capital, and (iv) 96,666 shares of Common Stock issuable upon exercise of Warrants owned by District 2 CF. Mr. Bigger also through his IRA and another account owns 177,670 shares of Common Stock and may be deemed the beneficial owner of 150,000 shares of Common Stock owned by his spouse Patricia Winter through an IRA and an aggregate of 300,000 shares held by his sons through IRAs.

    Ms. Winter holds 150,000 shares through an IRA.

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by District 2 CF, Mr. Bigger disclaims beneficial ownership of the shares held by Patricia Winter and his sons, and Ms. Winter disclaim beneficial ownership of the shares of Common Stock held by Mr. Bigger. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    12

    CUSIP No. 00507W206

    (b)Percent of class:

    The following percentages are based on 27,764,233 shares of Common Stock outstanding as of January 30, 2024, as represented in the Company’s Form S-3 filed February 2, 2024.

    As of the close of business on December 31, 2023, (i) each of Bigger Capital and Bigger GP may be deemed to beneficially own approximately 1.6% of the outstanding shares of Common Stock, (ii) each of District 2 CF, District 2, District 2 GP and District 2 Holdings may be deemed to beneficially own 3.0% of the outstanding shares of Common Stock, (iii) Mr. Bigger may be deemed to beneficially own approximately 6.8% of the outstanding shares of Common Stock and (iv) Ms. Winter may be deemed to beneficially own less than one percent of the outstanding Common Stock.

    Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons or affiliates of the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the “Blockers”), and the percentage set forth in Row 11 of the cover page for each Reporting Person as well in this Item 4(b) gives effect to the Blockers. Mr. Bigger may be deemed to be the beneficial owner of more than 4.99% of the outstanding shares of Common Stock. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the Warrants due to the Blockers.

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (ii)Shared power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (iii)Sole power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    (iv)Shared power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    Item 5.Ownership of Five Percent or Less of a Class.

    Not Applicable.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Bigger GP and Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock beneficially owned by Bigger Capital. District 2, District 2 GP, District 2 Holdings and Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock beneficially owned by District 2 CF. Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock held by Ms. Winter and the sons of Mr. Bigger.

    13

    CUSIP No. 00507W206

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1. Previously filed.

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    14

    CUSIP No. 00507W206

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 9, 2024

    BIGGER CAPITAL FUND, LP   BIGGER CAPITAL FUND GP, LLC
         
    By: Bigger Capital Fund GP, LLC, its general partner   By:

    /s/ Michael Bigger

            Michael Bigger
    By:

    /s/ Michael Bigger

        Managing Member
      Michael Bigger      
      Managing Member      
          DISTRICT 2 CAPITAL LP
             
    DISTRICT 2 CAPITAL FUND LP   By:

    /s/ Michael Bigger

            Michael Bigger
    By: District 2 GP LLC, its general partner     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger   DISTRICT 2 HOLDINGS LLC
      Managing Member      
          By:

    /s/ Michael Bigger

            Michael Bigger
    DISTRICT 2 GP LLC     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger  

    /s/ Michael Bigger

      Managing Member   MICHAEL BIGGER
           
           
         

    /s/ Patricia Winter

          PATRICIA WINTER

     

    15

     

     

    Get the next $ATNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNM

    DatePrice TargetRatingAnalyst
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    5/14/2024$25.00Overweight
    Stephens
    9/6/2023$11.60Buy
    HSBC Securities
    2/21/2023Outperform → Mkt Perform
    William Blair
    9/8/2022$20.00Overweight
    Cantor Fitzgerald
    8/25/2022$16.00Buy
    B. Riley Securities
    8/3/2021$57.00 → $45.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ATNM
    Financials

    Live finance-specific insights

    See more
    • Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

      -  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed

      11/18/24 8:00:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

      -  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm -  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients -  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 -  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover -  Iomab-B was

      2/18/23 4:30:00 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

      -  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,

      2/14/23 7:30:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ATNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ATNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Steinhart Richard I

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:33 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chell Jeffrey W.

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:19 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Almenoff June Sherie

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:02 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

      SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

      11/12/24 1:33:16 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

      SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

      11/8/24 6:51:04 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Actinium Pharmaceuticals Inc. (Delaware)

      SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

      11/4/24 11:47:21 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinum Pharma downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

      8/7/24 12:40:34 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Actinum Pharma with a new price target

      Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:54:25 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HSBC Securities initiated coverage on Actinum Pharma with a new price target

      HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60

      9/6/23 7:41:39 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

      -       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy -       Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy -       Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK, May 6

      5/6/25 8:45:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

      -  Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working -  ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option -  ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs NEW YORK, Apr

      4/28/25 8:30:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

      Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML modelsActimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignanciesActimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCINEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceutical

      4/28/25 8:00:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

      Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of

      3/27/23 7:00:00 AM ET
      $ATNM
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

      -Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development

      11/2/22 8:17:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)

      10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      5/9/25 5:27:35 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      5/9/25 5:00:08 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Actinium Pharmaceuticals Inc. (Delaware)

      10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      3/31/25 5:00:42 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care